Xcell Therapeutics, Inc.
KOSDAQTotal Valuation
Xcell Therapeutics, Inc. carries a market capitalization of 17.94B, placing it among publicly traded companies globally. Its enterprise value stands at 17.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 17.94B |
| Enterprise Value | 17.33B |
Valuation Ratios
The price-to-sales ratio is 6.95, and the price-to-book ratio stands at -0.31.
| PE Ratio | N/A |
| PS Ratio | 6.95 |
| PB Ratio | -0.31 |
| P/TBV Ratio | 3.12 |
| P/FCF Ratio | -1.78 |
| P/OCF Ratio | -1.72 |
Enterprise Valuation
| EV / Sales | 6.56 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Xcell Therapeutics, Inc. maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 81.06, indicating elevated leverage, while an interest coverage ratio of 86.64 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.88 |
| Quick Ratio | 1.22 |
| Debt / Equity | 81.06 |
| Debt / EBITDA | -0.47 |
| Interest Coverage | 86.64 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -77.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.39 |
Stock Price Statistics
Xcell Therapeutics, Inc.'s stock has declined approximately -56.70165% over the past 52 weeks. The 50-day moving average sits at 1,509.18, while the 200-day moving average is 1,893.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -56.70165% |
| 50-Day Moving Average | 1,509.18 |
| 200-Day Moving Average | 1,893.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Xcell Therapeutics, Inc. generated 2.64B in revenue and converted that into -11.31B in net income, yielding earnings per share of -857.79. EBITDA reached -11.21B, while operating income came in at -11.21B.
| Revenue | 2.64B |
| Gross Profit | -1.68B |
| Operating Income | -11.21B |
| Pretax Income | -11.31B |
| Net Income | -11.31B |
| EBITDA | -11.21B |
| EBIT | -11.21B |
| Earnings Per Share (EPS) | -857.79 |
Balance Sheet
Xcell Therapeutics, Inc. holds 6.32B in cash and equivalents against 5.30B in total debt, resulting in a net debt position of -1.42B. Total book value stands at -58.82B, with working capital of 4.57B providing operational flexibility.
| Cash & Cash Equivalents | 6.32B |
| Total Debt | 5.30B |
| Net Debt | -1.42B |
| Equity (Book Value) | -58.82B |
| Book Value Per Share | -4,462.47 |
| Working Capital | 4.57B |
Cash Flow
Xcell Therapeutics, Inc. produced -10.64B in operating cash flow over the past twelve months. After subtracting -347.69M in capital expenditures, free cash flow totaled -10.99B - equivalent to -833.58 per share.
| Operating Cash Flow | -10.64B |
| Capital Expenditures | -347.69M |
| Free Cash Flow | -10.99B |
| FCF Per Share | -833.58 |
Margins
Xcell Therapeutics, Inc. operates with a gross margin of -63.49, reflecting its pricing power and cost economics. The operating margin of -424.39 and net profit margin of -428.13 provide insight into operational efficiency.
| Gross Margin | -63.49 |
| Operating Margin | -424.39 |
| Pretax Margin | -428.13 |
| Profit Margin | -428.13 |
| EBITDA Margin | -424.39 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -46.69 |
| FCF Yield | -56.09 |
Scores
Xcell Therapeutics, Inc. posts an Altman Z-Score of -7.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.34 |